NEW YORK (GenomeWeb News) – Nanosphere said after the close of the market Thursday that the US Food and Drug Administration has designated its Gram-Positive Blood Culture nucleic acid test as a moderate-complexity test under CLIA.

The test runs on the firm's Verigene System and provides genes- and species-level detection for a broad panel of clinically significant Gram-positive bacteria. It also detects the mecA, vanA, and vanB genes that identify resistance to the antibiotics methicillin/oxacillin and vancomycin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.